DIAMETIC-PG2 contains Glimepiride 2 mg + Metformin HCl 500 mg SR + Pioglitazone 15 mg (Bilayered), providing complementary mechanisms for comprehensive glycaemic management in selected patients with Type 2 Diabetes. A strong PCD Cardiac-Diabetic offering.
Type 2 diabetes requiring combination therapy.
Yes, due to fluid retention.
Yes, particularly with Glimepiride.
Monitor glucose, body weight and signs of edema or breathlessness. Pioglitazone requires particular caution in patients at risk for heart failure. (DailyMed)
Hypoglycemia, weight gain, edema, nausea, headache and gastrointestinal discomfort. Pioglitazone may cause fluid retention and can worsen heart failure. (DailyMed)
DIAMETIC-PG2: Glimepiride increases insulin secretion, Metformin reduces hepatic glucose output and Pioglitazone improves insulin sensitivity in peripheral tissues.
